Name | sgc−cbp30 |
---|---|
Synonyms |
2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-benzimidazole
1H-Benzimidazole, 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-4-isoxazolyl)-1-[(2S)-2-(4-morpholinyl)propyl]- 2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole 2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(4-morpholinyl)propyl]-1H-benzimidazole SGC-CBP30 |
Description | SGC-CBP30 is a potent CREBBP/EP300 bromodomain inhibitor with IC50 of 21-69 and 38 nM for CREBBP and EP300 bromodomains, respectively.IC50 Value: 21-69 nM(for CREBBP); 38 nM(for EP300)Target: Othersin vivo: SGC-CBP30 is a highly potent and selective p300/CBP bromodomain inhibitor (IC50 ~0.021-0.069 uM for CBP and ~0.038 uM for p300). It has 40-fold selectivity for CBP over BRD4. It accelerated FRAP recovery at 1 uM. in vivo: N/A |
---|---|
Related Catalog | |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 678.0±55.0 °C at 760 mmHg |
Molecular Formula | C28H33ClN4O3 |
Molecular Weight | 509.040 |
Flash Point | 363.8±31.5 °C |
Exact Mass | 508.224121 |
PSA | 65.55000 |
LogP | 5.29 |
Vapour Pressure | 0.0±2.1 mmHg at 25°C |
Index of Refraction | 1.629 |
Storage condition | 2-8°C |